Literature DB >> 25791527

Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice.

Yuji Ishida1, Chihiro Yamasaki2, Ami Yanagi2, Yasumi Yoshizane2, Kazuyuki Fujikawa3, Koichi Watashi4, Hiromi Abe5, Takaji Wakita4, C Nelson Hayes5, Kazuaki Chayama5, Chise Tateno6.   

Abstract

The molecular mechanisms underlying the hepatitis B virus (HBV) life cycle are poorly understood because of the lack of appropriate in vitro infection models. Herein, we report a highly effective in vitro HBV infection system using fresh human hepatocytes (HHs) isolated from chimeric mice with humanized livers. After the inoculation of sera collected from HBV-infected chimeric mice or patients to HHs, we measured levels of HBV DNA, mRNA, covalently closed circular DNA, and viral protein expression in HHs. We investigated the neutralization activity of hepatitis B immune globulin and the effects of siRNA against sodium taurocholate-cotransporting polypeptide and clathrin heavy chain on HBV infection. We confirmed the expression of viral antigens in HHs and the presence of extracellular HBV DNA and hepatitis B surface antigen. The maximum infection rate was approximately 80%. Lamivudine and hepatitis B immune globulin treatment reduced HBV DNA levels in a dose-dependent manner. Knockdown of sodium taurocholate-cotransporting polypeptide and clathrin heavy chain significantly reduced the levels of hepatitis B surface antigen. Infection was successfully established using different donor HHs and inocula. Elevation of extracellular HBV DNA levels and the increase of HBV-positive HHs were blocked by continuous hepatitis B immune globulin treatment, indicating virus spread in this model. Chimeric mouse-derived HHs provide a robust in vitro infection model that can completely support the HBV life cycle.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25791527     DOI: 10.1016/j.ajpath.2015.01.028

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  37 in total

1.  Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM).

Authors:  Andrew N Lane; Richard M Higashi; Teresa W-M Fan
Journal:  Metabolomics       Date:  2016-06-29       Impact factor: 4.290

2.  Fungus-Derived Neoechinulin B as a Novel Antagonist of Liver X Receptor, Identified by Chemical Genetics Using a Hepatitis C Virus Cell Culture System.

Authors:  Syo Nakajima; Koichi Watashi; Hirofumi Ohashi; Shinji Kamisuki; Jesus Izaguirre-Carbonell; Andrew Tae-Jun Kwon; Harukazu Suzuki; Michiyo Kataoka; Senko Tsukuda; Maiko Okada; Meng Ling Moi; Toshifumi Takeuchi; Minetaro Arita; Ryosuke Suzuki; Hideki Aizaki; Takanobu Kato; Tadaki Suzuki; Hideki Hasegawa; Tomohiko Takasaki; Fumio Sugawara; Takaji Wakita
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

3.  Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection.

Authors:  Yuji Ishida; Masakazu Kakuni; Bo-Ram Bang; Go Sugahara; Daryl T-Y Lau; Chise Tateno-Mukaidani; Meng Li; Michael Gale; Takeshi Saito
Journal:  J Interferon Cytokine Res       Date:  2019-03       Impact factor: 2.607

4.  Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor.

Authors:  Adrien Decorsière; Henrik Mueller; Pieter C van Breugel; Fabien Abdul; Laetitia Gerossier; Rudolf K Beran; Christine M Livingston; Congrong Niu; Simon P Fletcher; Olivier Hantz; Michel Strubin
Journal:  Nature       Date:  2016-03-17       Impact factor: 49.962

5.  Establishment and Characterization of an HBV Viral Spread and Infectious System following Long-Term Passage of an HBV Clinical Isolate in the Primary Human Hepatocyte and Fibroblast Coculture System.

Authors:  Yang Liu; Dmytro Kornyeyev; Lindsey May; Dong Han; Thomas Aeschbacher; Silvia Chang; Ross Martin; Hongmei Mo; Becket Feierbach
Journal:  J Virol       Date:  2022-08-29       Impact factor: 6.549

6.  Novel Neplanocin A Derivatives as Selective Inhibitors of Hepatitis B Virus with a Unique Mechanism of Action.

Authors:  Masaaki Toyama; Koichi Watashi; Masanori Ikeda; Atsuya Yamashita; Mika Okamoto; Kohji Moriishi; Masamichi Muramatsu; Takaji Wakita; Ashoke Sharon; Masanori Baba
Journal:  Antimicrob Agents Chemother       Date:  2022-05-23       Impact factor: 5.938

Review 7.  HBV culture and infectious systems.

Authors:  C Nelson Hayes; Kazuaki Chayama
Journal:  Hepatol Int       Date:  2016-03-02       Impact factor: 6.047

8.  The aryl hydrocarbon receptor-cytochrome P450 1A1 pathway controls lipid accumulation and enhances the permissiveness for hepatitis C virus assembly.

Authors:  Hirofumi Ohashi; Kazane Nishioka; Syo Nakajima; Sulyi Kim; Ryosuke Suzuki; Hideki Aizaki; Masayoshi Fukasawa; Shinji Kamisuki; Fumio Sugawara; Naoko Ohtani; Masamichi Muramatsu; Takaji Wakita; Koichi Watashi
Journal:  J Biol Chem       Date:  2018-10-31       Impact factor: 5.157

9.  MafF Is an Antiviral Host Factor That Suppresses Transcription from Hepatitis B Virus Core Promoter.

Authors:  Marwa K Ibrahim; Tawfeek H Abdelhafez; Junko S Takeuchi; Kosho Wakae; Masaya Sugiyama; Masataka Tsuge; Masahiko Ito; Koichi Watashi; Mohamed El Kassas; Takanobu Kato; Asako Murayama; Tetsuro Suzuki; Kazuaki Chayama; Kunitada Shimotohno; Masamichi Muramatsu; Hussein H Aly; Takaji Wakita
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

10.  Humanized liver mouse model with transplanted human hepatocytes from patients with ornithine transcarbamylase deficiency.

Authors:  Go Sugahara; Chihiro Yamasaki; Ami Yanagi; Suzue Furukawa; Yuko Ogawa; Akinari Fukuda; Shin Enosawa; Akihiro Umezawa; Yuji Ishida; Chise Tateno
Journal:  J Inherit Metab Dis       Date:  2020-12-30       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.